GlassScriptPhysician profile
Kathryn B Reed
NPI 1699974832
$5,616.32
in general payments reported to CMS, 2019-2025
27 companies · $1,295 in 2025
The $1,295 reported for 2025 was more than what 97% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
See the full distribution for Pediatrics (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,417 · 2022: $1,475 · 2023: $735 · 2024: $694 · 2025: $1,295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,725.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,724.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,261.86 | 2021-2025 | Dupixent |
| Glaxosmithkline, LLC. | $891.23 | 2021-2025 | Nucala, Trelegy Ellipta |
| Genzyme Corporation | $874.53 | 2021-2025 | |
| Pfizer INC. | $539.42 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $507.00 | 2021-2025 | Fasenra, Tezspire |
| Grifols USA, LLC | $264.08 | 2021-2023 | Xembify |
| Takeda Pharmaceuticals U.S.A., INC. | $183.89 | 2021-2022 | |
| Csl Behring | $166.19 | 2021-2023 | Hizentra |
| Genentech USA, INC. | $87.63 | 2022-2024 | Xolair |
| Kaleo, INC. | $75.14 | 2021-2023 | Auvi-Q |
| Phadia US INC. | $68.17 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $67.60 | 2023-2024 | |
| Biocryst US Sales Co., LLC | $66.89 | 2021-2022 | |
| Aytu Biopharma, INC. | $64.99 | 2022-2024 | Karbinal |
| Teva Pharmaceuticals USA, INC. | $61.26 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $60.74 | 2022 | |
| Amgen INC. | $56.98 | 2021-2025 | Tezspire |
| Octapharma USA, INC. | $49.76 | 2021 | |
| Seqirus USA INC | $47.67 | 2025 | Flucelvax, Fluad |
| Pharming Healthcare, INC. | $42.61 | 2021-2022 | |
| Adma Biomanufacturing LLC | $39.03 | 2021 | |
| Leo Pharma INC. | $39.02 | 2022 | |
| Alk-Abello, INC | $30.34 | 2022 | |
| Aimmune Therapeutics, INC. | $27.64 | 2022 | |
| Corium, LLC | $16.99 | 2022 | |
| Supernus Pharmaceuticals, INC. | $12.95 | 2022 | |
| Optinose US, INC. | $12.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Reed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.